p.106 抽出テキスト
953. Berge E, Whiteley W, Audebert H, De Marchis GM, Fonseca AC, Padiglioni C, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J 2021;6:I–LXII. https://doi.org/10.1177/2396987321989865 954. LeCouffe NE, Kappelhof M, Treurniet KM, Lingsma HF, Zhang G, van den Wijngaard IR, et al. 2B, 2C, or 3: what should be the angiographic target for endovascular treatment in ischemic stroke? Stroke 2020;51:1790–6. https://doi.org/10.1161/strokeaha. 119.028891 955. Mistry EA, Hart KW, Davis LT, Gao Y, Prestigiacomo CJ, Mittal S, et al. Blood pressure management after endovascular therapy for acute ischemic stroke: the BEST-II randomized clinical trial. JAMA 2023;330:821–31. https://doi.org/10.1001/jama.2023.14330 956. Lee M, Ovbiagele B, Hong KS, Wu Y-L, Lee J-E, Rao NM, et al. Effect of blood pressure lowering in early ischemic stroke: meta-analysis. Stroke 2015;46:1883–9. https://doi. org/10.1161/strokeaha.115.009552 957. Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet 2019;393:877–88. https://doi.org/10.1016/s0140-6736(19)30038-8 958. Mazighi M, Richard S, Lapergue B, Sibon I, Gory B, Berge J, et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial. Lancet Neurol 2021;20:265–74. https://doi.org/10.1016/s1474-4422(20)30483-x 959. Yang P, Song L, Zhang Y, Zhang X, Chen X, Li Y, et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. Lancet 2022; 400:1585–96. https://doi.org/10.1016/s0140-6736(22)01882-7 960. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gąsecki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J 2021;6: Xlviii–lxxxix. https://doi.org/10.1177/23969873211012133 961. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid bloodpressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013;368:2355–65. https://doi.org/10.1056/NEJMoa1214609 962. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016;375:1033–43. https://doi.org/10.1056/NEJMoa1603460 963. Moullaali TJ, Wang X, Woodhouse LJ, Law ZK, Delcourt C, Sprigg N, et al. Lowering blood pressure after acute intracerebral haemorrhage: protocol for a systematic review and meta-analysis using individual patient data from randomised controlled trials participating in the blood pressure in acute stroke collaboration (BASC). BMJ Open 2019;9:e030121. https://doi.org/10.1136/bmjopen-2019-030121 964. American College of Obstetricians and Gynecologists. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol 2020;135: e237–60. https://doi.org/10.1097/aog.0000000000003891 965. Garovic VD, Dechend R, Easterling T, Karumanchi SA, Baird SM, Magee LA, et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension 2022;79: e21–41. https://doi.org/10.1161/hyp.0000000000000208 966. Magee LA, Nicolaides KH, von Dadelszen P. Preeclampsia. N Engl J Med 2022;386: 1817–32. https://doi.org/10.1056/NEJMra2109523 967. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. Lancet 2002;359:1877–90. https://doi.org/10. 1016/s0140-6736(02)08778-0 968. Poon LC, Magee LA, Verlohren S, Shennan A, von Dadelszen P, Sheiner E, et al. A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: compiled by the pregnancy and non-communicable diseases committee of FIGO (the International Federation of Gynecology and Obstetrics). Int J Gynaecol Obstet 2021;154 Suppl 1:3–31. https:// doi.org/10.1002/ijgo.13763 969. Muhammad S, Usman H, Dawha YM, Yahya A, Yekeen A, Bako B. Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: a randomized controlled trial. Pregnancy Hypertens 2022;29: 1–6. https://doi.org/10.1016/j.preghy.2022.05.001 970. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327:955–60. https://doi.org/10.1136/bmj.327.7421.955 971. Wu HZ, Cheng Y, Yu D, Li J-B, Jiang Y-F, Zhu Z-N. Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. Hypertens Pregnancy 2022;41:126–38. https://doi.org/10.1080/10641955.2022.2056196 972. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing noncardiac surgery. Eur Heart J 2022;43:3826–924. https://doi.org/10.1093/eurheartj/ehac270 973. Lizano-Díez I, Poteet S, Burniol-Garcia A, Cerezales M. The burden of perioperative hypertension/hypotension: a systematic review. PLoS One 2022;17:e0263737. https://doi.org/10.1371/journal.pone.0263737 974. Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P, et al. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. JAMA 2017;318:1346–57. https://doi.org/10.1001/jama.2017.14172 975. Sanders RD, Hughes F, Shaw A, Thompson A, Bader A, Hoeft A, et al. Perioperative quality initiative consensus statement on preoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth 2019;122:552–62. https://doi.org/10.1016/j. bja.2019.01.018 976. Messina A, Robba C, Calabrò L, Zambelli D, Iannuzzi F, Molinari E, et al. Association between perioperative fluid administration and postoperative outcomes: a 20-year systematic review and a meta-analysis of randomized goal-directed trials in major visceral/noncardiac surgery. Crit Care 2021;25:43. https://doi.org/10.1186/s13054-021- 03464-1 977. Meng L, Yu W, Wang T, Zhang L, Heerdt PM, Gelb AW. Blood pressure targets in perioperative care. Hypertension 2018;72:806–17. https://doi.org/10.1161/hypertensionaha. 118.11688 978. Wanner PM, Wulff DU, Djurdjevic M, Korte W, Schnider TW, Filipovic M. Targeting higher intraoperative blood pressures does not reduce adverse cardiovascular events following noncardiac surgery. J Am Coll Cardiol 2021;78:1753–64. https://doi.org/10. 1016/j.jacc.2021.08.048 979. Blessberger H, Lewis SR, Pritchard MW, Fawcett LJ, Domanovits H, Schlager O, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev 2019;9:CD013438. https://doi.org/10.1002/14651858.CD013438 980. McGory ML, Maggard MA, Ko CY. A meta-analysis of perioperative beta blockade: what is the actual risk reduction? Surgery 2005;138:171–9. https://doi.org/10.1016/j. surg.2005.03.022 981. Kertai MD, Cooter M, Pollard RJ, Buhrman W, Aronson S, Mathew JP, et al. Is compliance with surgical care improvement project cardiac (SCIP-Card-2) measures for perioperative β-blockers associated with reduced incidence of mortality and cardiovascular-related critical quality indicators after noncardiac surgery? Anesth Analg 2018;126:1829–38. https://doi.org/10.1213/ane.0000000000002577 982. Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Côté EP, et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the vascular events in noncardiac surgery patIents cOhort evaluatioN prospective cohort. Anesthesiology 2017;126:16–27. https://doi.org/10.1097/aln.0000000000001404 983. Shiffermiller JF, Monson BJ, Vokoun CW, Beachy MW, Smith MP, Sullivan JN, et al. Prospective randomized evaluation of preoperative angiotensin-converting enzyme inhibition (PREOP-ACEI). J Hosp Med 2018;13:661–7. https://doi.org/10. 12788/jhm.3036 984. Hollmann C, Fernandes NL, Biccard BM. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth Analg 2018;127:678–87. https://doi.org/10.1213/ane.0000000000002837 985. Ackland GL, Patel A, Abbott TEF, Begum S, Dias P, Crane DR, et al. Discontinuation vs. continuation of renin–angiotensin system inhibition before non-cardiac surgery: the SPACE trial. Eur Heart J 2024;45:1146–55. https://doi.org/10.1093/eurheartj/ehad716 986. McEvoy MD, Gupta R, Koepke EJ, Feldheiser A, Michard F, Levett D, et al. Perioperative quality initiative consensus statement on postoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth 2019;122:575–86. https://doi.org/ 10.1016/j.bja.2019.01.019 987. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, et al. Person-centered care—ready for prime time. Eur J Cardiovasc Nurs 2011;10:248–51. https://doi.org/10. 1016/j.ejcnurse.2011.06.008 988. Krist AH, Tong ST, Aycock RA, Longo DR. Engaging patients in decision-making and behavior change to promote prevention. Stud Health Technol Inform 2017; 240:284–302. https://doi.org/10.3233/ISU-170826 989. Johnson RA, Huntley A, Hughes RA, Hughes RA, Cramer H, Turner KM, et al. Interventions to support shared decision making for hypertension: a systematic review of controlled studies. Health Expect 2018;21:1191–207. https://doi.org/10. 1111/hex.12826 990. Johnson RL, Roter D, Powe NR, Cooper LA. Patient race/ethnicity and quality of patient–physician communication during medical visits. Am J Public Health 2004;94: 2084–90. https://doi.org/10.2105/ajph.94.12.2084 991. Williams MV, Davis T, Parker RM, Weiss BD. The role of health literacy in patientphysician communication. Fam Med 2002;34:383–9. 992. Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;3:CD006887. https://doi.org/10.1002/14651858.CD006887.pub4 993. Ma C, Zhou Y, Zhou W, Huang C. Evaluation of the effect of motivational interviewing counselling on hypertension care. Patient Educ Couns 2014;95:231–7. https://doi.org/ 10.1016/j.pec.2014.01.011 994. Huang X, Xu N, Wang Y, Sun Y, Guo A. The effects of motivational interviewing on hypertension management: a systematic review and meta-analysis. Patient Educ Couns 2023;112:107760. https://doi.org/10.1016/j.pec.2023.107760 ESC Guidelines 4017 Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026